Biocon Biologics has one of the deepest portfolios of biosimilars in the industry. Our long-term investments in R&D have yielded several molecules in oncology, of which three have already been commercialized in markets globally.
Approved in ~80 countries, including the U.S., EU countries, UK, Canada, Australia, NZ, many Emerging Market (EM) countries
Commercialized in the U.S., EU countries, Canada, Australia, some EM countries
Preclinical
Clinical
Filed
Approved
Launched
Approved in 100+ countries, including the U.S., EU countries, UK, Canada, Australia, NZ & many EM countries
Commercialized in the U.S., EU countries, Australia, Canada, India, Brazil, Argentina, Turkey, Indonesia etc.
Preclinical
Clinical
Filed
Approved
Launched
Approved in ~70 countries, including EU countries, UK, Canada, Australia, NZ & many EM countries; Filed in the U.S.
Commercialized in EU countries, Australia, Canada, India, Malaysia
Preclinical
Clinical
Filed
Approved
Launched
Preclinical
Clinical
Filed
Approved
Launched
Preclinical
Clinical
Filed
Approved
Launched